By
A new study led by MIT Sloan Prof. Andrew W. Lo finds that borrowing ideas and tools from the gaming community can improve online teaching techniques and improve learning outcomes for students.
Vaccines are an especially risky proposition for pharmaceutical manufacturers since the costs are higher than for other types of drugs and demand could drop drastically once a crisis is over.
By
MIT Sloan and CSAIL researchers apply artificial intelligence techniques to one of the largest datasets of clinical trial outcomes to handicap the drug and device approval process
By
The MIT Laboratory for Financial Engineering (LFE) and Informa Pharma Intelligence announced a new initiative, Project ALPHA (Analytics for Life-sciences Professionals and Healthcare Advocates).
Researchers launched an in-house Data Science and Artificial Intelligence (DSAI) challenge to beat MIT’s machine-learning models for predicting clinical trial outcomes. The results are now available.
By
MIT researchers have developed a methodology for systematically tracking the outcomes of academic licensing transactions as a means of increasing funding to bridging the “valley of death.”
By
MIT study explores the key factors behind patient outcomes in clinical trials evaluating new treatments for non-small-cell lung cancer.
By
Since 2019, hundreds of first-year MBA students have taken ID Lab, a unique course dedicated to discovering and developing leadership skills.
By
The studies describe new methods for accelerating drug approvals during pandemics and for providing more accurate measures of the probabilities of success for clinical trials of vaccines.
By
During September's iLead Speaker Series event, Analysis Group’s Martha Samuelson, SF ’86, and Rebecca Kirk Fair, MBA ’02, discussed their professional journeys, as well as the culture and leadership of their firm.
